The therapeutic effects of tenidap in canine experimental osteoarthritis: Relationship with biochemical markers

Journal of Rheumatology

Volumn 24, Issue 5, 1997, Pages 916-925

  Jovanovic, Dragan ^b   Caron, John P ^b   Martel Pelletier, Johanne ^b   Fernandes, Julio C ^b   Ricketts, Tony ^b   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b NONE

Author keywords

CHONDROPROTECTION; EXPERIMENTAL OSTEOARTHRITIS; INTERLEUKIN 1; METALLOPROTEASES; TENIDAP

Indexed keywords

BIOCHEMICAL MARKER; COLLAGENASE; GELATINASE; INTERLEUKIN 1; METALLOPROTEINASE; OMEPRAZOLE; STROMELYSIN; TENIDAP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOG; INCIDENCE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; CARTILAGE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOGS; GELATINASES; INDOLES; INTERLEUKIN-1; KNEE JOINT; MATRIX METALLOPROTEINASE 3; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 0030907591     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hochberg MC, Kasper J, Williamson J, Skinner A, Fried LP: The contribution of osteoarthritis to disability: Preliminary data from the women's health and aging study. J Rheumatol 1995;(suppl 43)22:16-8.
2. Badley EM: The effect of osteoarthritis on disability and health care use in Canada. J Rheumatol 1995;(suppl 43)22:19-22.
3. Gabriel SE, Crowson CS, O'Fallon WM: Costs of osteoarthritis: Estimates from a geographically defined population. J Rheumatol 1995;(suppl 43)22:23-5.
4. Pelleter J-P, Martel-Pelletier J, Howell DS: Etiopathogenesis of osteoarthritis. In: McCarthy DJ, Koopman WJ, eds. Arthritis and Allied Conditions. A Textbook of Rheumatology, 13th ed. Pennsylvania: Lea & Febiger, 1996:1969-84.
5. Dieppe P: Therapeutic targets in osteoarthritis. J Rheumatol 1995;(suppl 43)22:136-9.
6. Lohmander LS, Hoermer LA, Lark MW: Metalloproteinases, tissue inhibitor and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
7. Pelletier J-P, DiBattista JA, Roughley P, McColluni R, Martel-Pelletier J: Cytokines and inflammation in cartilage degradation. In: Moskowitz RW, ed. Osteoarthritis, Edition of Rheumatic Disease Clinics of North America. Philadelphia: WB Saunders, 1993:545-68.
8. Dean DD: Proteinase-mediated cartilage degradation in osteoarthritis. Rev Semin Arthritis Rheum 1991;20:2-11.
9. Martel-Pelletier J, Mineau F, Tardif G, et al: Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts. J Rheumatol 1996;23:24-31.
10. Pelletier J-P, McCollum R, DiBattista J, Loose LD, Cloutier JM, Martel-Pelletier J: Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993;36:1517-27.
11. Sipe JD, Bartle LM, Loose LD: Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J Immunol 1992;148:480-4.
12. Fernandas JC, Martel-Pelletier J, Otterness I, et al: Effects of tenidap on canine experimental osteoarthritis. I. Morphological analysis and metalloprotease analysis. Arthritis Rheum 1995;38:1290-303.
13. Davis JS, Loose LD, Borger AP: Clinical efficacy of CP-66, 248 [5-chloro-2, 3-dihydro-2-oxo-3(2-thienylcarbonyl)-indole-1-carboxamide] in osteoarthritis (abstr). Arthritis Rheum 1988;(suppl 4)31:S72.
14. Pelletier J-P, Mineau F, Raynauld J-P, Woessner JF Jr, Gunja-Smith Z, Martel-Pelletier J: Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. Arthritis Rheum 1994;37:414-23.
15. Mankin HJ, Dorfman H, Lipiello L, Zarins A: Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg 1971;53:523-31.
16. Dean DD, Martel-Pelletier J, Pelletier J-P, Howell DS, Woessner JF Jr: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85.
17. Pelletier J-P, Mineau F, Faure MP, Martel-Pelletier J: Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 1990;33:1466-76.
18. 3H) acetylated collagen. Anal Biochem 1985;148:174-81.
19. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O'Connor BL, Brandt DA: Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992;35:1150-9.
20. Chavira RJ Jr, Burnett TJ, Hageman JH: Assaying proteinases with azocoll. Anal Biochem 1984;136:446-50.
21. Harris ED Jr, Krane SM: An endopeptidase from rheumatoid synovial tissue culture. Biochem Biophys Res Commun 1972;258:566-76.
22. Bhardwaj N; Lau LL; Rivelis M, Steinman RM: Interleukin-1 production by mononuclear cells from rheumatoid synovial effusions. Cell Immunol 1988;114:405-23.
23. Pelletier J-P, Fernandes JC, Caron JP, et al: Effects of tenidap on canine experimental osteoarthritis under therapeutic conditions (abstr). Arthritis Rheum 1995;(suppl)35:S162.
24. Pelletier J-P, DiBattista JA, Raynauld JP, Wilhelm S, Martel-Pelletier J: The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1 and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995;72:578-86.
25. Caron JP, Fernandes JC, Martel-Pelletier J, et al: Intraarticular injections of interleukin-1 receptor antagonist exert a chondroprotective effect in experimental osteoarthritis: Suppression of collagenase expression. Arthritis Rheum 1996;39:1535-44.
26. van Beuningen HM, van der Kraan PM, Arnitz OJ, van den Berg WB: Transforming growth factor-ß1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 1994;71:279-90.
27. van de Loo FA, Arntz OJ, Otterness IG, van den Berg WB: Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin 1 antibodies in experimental arthritis. J Rheumatol 1992;19:348-56.
28. Celeste AJ, lannazzi JA, Taylor RC, et al: Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 1990;87:9843-7.
29. Ounissi-Benkalha H, Pelletier J-P, Tardif G, et al: In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. J Rheumatol 1996;23:16-23.
30. Moore PF, Larson DL, Otterness IG, et al: Tenidap, a structurally novel drug for the treatment of arthritis. Antiinflammatory and analgesic activity. Inflamm Research 1996;45:54-64.